Abstract

Mitochondrial diseases (MD) are rare disorders caused by deficiency of the mitochondrial respiratory chain, which provides energy in each cell. They are characterized by a high clinical and genetic heterogeneity and in most patients, the responsible gene is unknown. Diagnosis is based on the identification of the causative gene that allows genetic counseling, prenatal diagnosis, understanding of pathological mechanisms, and personalized therapeutic approaches. Despite the emergence of Next Generation Sequencing (NGS), to date, more than one out of two patients has no diagnosis in the absence of identification of the responsible gene. Technologies currently used for detecting causal variants (genetic alterations) is far from complete, leading many variants of unknown significance (VUS) and mainly based on the use of whole exome sequencing thus neglecting the identification of non-coding variants. The complexity of human genome and its regulation at multiple levels has led biologists to develop several assays to interrogate the different aspects of biological processes. While one-dimension single omics investigation offers a peek of this complex system, the combination of different omics data allows the discovery of coherent signatures. The community of computational biologists and bioinformaticians, in order to integrate data from different omics, has developed several approaches and tools. However, it is difficult to understand which suits the best to predict diverse phenotypic outcome. First attempts to use multi-omics approaches showed an improvement of the diagnostic power. However, we are far from a complete understanding of MD and their diagnosis. After reviewing multi-omics algorithms developed in the latest years, we are proposing here a novel data-driven classification and we will discuss how multi-omics will change and improve the diagnosis of MD. Due to the growing use of multi-omics approaches in MD, we foresee that this work will contribute to set up good practices to perform multi-omics data integration to improve the prediction of phenotypic outcomes and the diagnostic power of MD.

Highlights

  • Mitochondrial diseases (MD) are rare disorders caused by a deficiency of the mitochondrial respiratory chain, which provides energy to individual cells through oxidative phosphorylation (Munnich and Rustin, 2001)

  • MD can be caused by pathogenic variants affecting either mitochondrial DNA or nuclear genes (Alston et al, 2017)

  • The advent of high-throughput sequencing (HTS) and its implementation in hospital laboratories has improved the performance of diagnosis which today is based on the analysis of the entire mitochondrial DNA (mtDNA) and large panels of nuclear genes (Vasli et al, 2012; Plutino et al, 2018)

Read more

Summary

Introduction

Mitochondrial diseases (MD) are rare disorders caused by a deficiency of the mitochondrial respiratory chain, which provides energy to individual cells through oxidative phosphorylation (Munnich and Rustin, 2001). These diseases are extremely heterogeneous, both clinically and genetically, making their diagnosis a real challenge (Gorman et al, 2016). Mitochondria have their own genome, most proteins involved in their biogenesis are encoded by nuclear genes. In one out of two patients, the gene responsible remains unknown

Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call